Wall Street Associates’s BioMarin Pharmaceuticals BMRN Stock Holding History

Wall Street Associates’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$311K	Sell	3,750 -7	-0.2%	-$602	0.21%	171
2016 Q3	$348K	Hold	3,757	–	–	0.12%	174
2016 Q2	$292K	Hold	3,757	–	–	0.12%	180
2016 Q1	$310K	Hold	3,757	–	–	0.13%	177
2015 Q4	$394K	Hold	3,757	–	–	0.11%	237
2015 Q3	$396K	Sell	3,757 -2,806	-43%	-$375K	0.08%	241
2015 Q2	$898K	Sell	6,563 -2,103	-24%	-$261K	0.08%	219
2015 Q1	$1.08M	Hold	8,666	–	–	0.1%	201
2014 Q4	$783K	Hold	8,666	–	–	0.08%	214
2014 Q3	$625K	Buy	8,666 +1,185	+16%	+$77.9K	0.06%	232
2014 Q2	$465K	Sell	7,481 -1,580	-17%	-$95.5K	0.04%	266
2014 Q1	$618K	Buy	9,061 +3,905	+76%	+$288K	0.05%	249
2013 Q4	$363K	Sell	5,156 -50	-1%	-$3.4K	0.03%	287
2013 Q3	$376K	Sell	5,206 -100	-2%	-$6.65K	0.04%	278
2013 Q2	$296K	Buy	+5,306	New	+$331K	0.03%	263

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wall Street Associates's BMRN Position: Q4 2016 in Review

Wall Street Associates reduced its BioMarin Pharmaceuticals (BMRN) stake by 0.19% in Q4 2016, selling an estimated $602 and leaving 3,750 shares worth $311K. The position accounts for 0.21% of the portfolio, ranked #171.

Wall Street Associates first reported a position in BMRN in Q2 2013 and has held it in 15 quarters since. The position peaked at $1.08M in Q1 2015. 415 funds tracked by Wall St. Rank hold BMRN as of Q4 2016.

Wall Street Associates held 3,750 shares of BioMarin Pharmaceuticals worth $311K as of Q4 2016.
Wall Street Associates sold 7 BioMarin Pharmaceuticals shares in Q4 2016, an estimated $602.
BioMarin Pharmaceuticals made up 0.21% of Wall Street Associates's portfolio in Q4 2016, its #171 holding.
Wall Street Associates first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
Wall Street Associates's BioMarin Pharmaceuticals position peaked at $1.08M in Q1 2015.
415 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2016.

Based on Wall Street Associates's 13F filing for Q4 2016, filed 18 Jan 2017.